ClinVar Miner

Submissions for variant NM_000046.5(ARSB):c.215T>G (p.Leu72Arg)

gnomAD frequency: 0.00001  dbSNP: rs397514441
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory of Diagnosis and Therapy of Lysosomal Disorders, University of Padova RCV000677516 SCV000803026 likely pathogenic Mucopolysaccharidosis type 6 2018-01-01 criteria provided, single submitter curation In vitro functional studies supportive of a damaging effect on the gene product (low to no ARSB activity in homozygotes; PS3); Absent from GnomAD (PM2); Reputable source identifies as pathogenic (PP5)
Labcorp Genetics (formerly Invitae), Labcorp RCV000677516 SCV000955328 pathogenic Mucopolysaccharidosis type 6 2023-12-08 criteria provided, single submitter clinical testing This sequence change replaces leucine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 72 of the ARSB protein (p.Leu72Arg). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with mucopolysaccharidosis type VI (PMID: 16435196, 17458871, 25190157; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 559740). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ARSB protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000677516 SCV001370604 pathogenic Mucopolysaccharidosis type 6 2020-05-07 criteria provided, single submitter clinical testing Variant summary: ARSB c.215T>G (p.Leu72Arg) results in a non-conservative amino acid change located in the Sulfatase, N-terminal domain (IPR000917) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 5.5e-06 in 182450 control chromosomes. c.215T>G has been reported in the literature in multiple homozygous and compound heterozygous individuals affected with Mucopolysaccharidosis Type VI (Maroteaux-Lamy Syndrome) with early onset and classical, rapidly progressing disease phenotype in the homozygotes (Petry_2005, Karageorgos_2007). These data indicate that the variant is very likely to be associated with disease. One of these publications also reported very low or undetectable ASB protein levels and undetectable enzymatic activities in skin fibroblasts derived from homozygous patients (Karageorgos_2007). Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, and both of them classified the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Fulgent Genetics, Fulgent Genetics RCV000677516 SCV002785020 likely pathogenic Mucopolysaccharidosis type 6 2021-10-12 criteria provided, single submitter clinical testing
Revvity Omics, Revvity RCV000677516 SCV003817884 pathogenic Mucopolysaccharidosis type 6 2022-03-14 criteria provided, single submitter clinical testing
Baylor Genetics RCV000677516 SCV004209214 pathogenic Mucopolysaccharidosis type 6 2024-01-02 criteria provided, single submitter clinical testing
Neuberg Centre For Genomic Medicine, NCGM RCV000677516 SCV005400795 pathogenic Mucopolysaccharidosis type 6 2023-06-22 criteria provided, single submitter clinical testing The observed missense variant c.215T>G(p.Leu72Arg) in ARSB gene has been reported previously in mulitple individual(s) with Mucopolysaccharidosis type VI. This variant is present in a mutational hotspot. A different missense cariant (c.215T>C, p.Leu72Pro) has been previously reported as pathogenic at the same position (Tomanin R, et al., 2018; Zheng J, et al., 2014). This variant is reported with the allele frequency 0.001% in the gnomAD Exomes. This variant has been reported to the ClinVar database as Pathogenic/Likely Pathogenic by multiple submitters. The amino acid Leu at position 72 is changed to a Arg changing protein sequence and it might alter its composition and physico-chemical properties. Multiple lines of computational evidence (Polyphen - Possibly damaging, SIFT – Damaging and MutationTaster - Disease causing) predict a damaging effect on protein structure and function for this variant. The residue is conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Pathogenic.
Natera, Inc. RCV000677516 SCV001457630 likely pathogenic Mucopolysaccharidosis type 6 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.